全文获取类型
收费全文 | 138054篇 |
免费 | 9737篇 |
国内免费 | 634篇 |
专业分类
耳鼻咽喉 | 1704篇 |
儿科学 | 3469篇 |
妇产科学 | 2546篇 |
基础医学 | 17669篇 |
口腔科学 | 2921篇 |
临床医学 | 13726篇 |
内科学 | 28241篇 |
皮肤病学 | 1821篇 |
神经病学 | 12121篇 |
特种医学 | 5469篇 |
外科学 | 22110篇 |
综合类 | 1974篇 |
现状与发展 | 1篇 |
一般理论 | 178篇 |
预防医学 | 12617篇 |
眼科学 | 2942篇 |
药学 | 9751篇 |
2篇 | |
中国医学 | 207篇 |
肿瘤学 | 8956篇 |
出版年
2023年 | 676篇 |
2022年 | 1056篇 |
2021年 | 2588篇 |
2020年 | 1482篇 |
2019年 | 2419篇 |
2018年 | 2948篇 |
2017年 | 2136篇 |
2016年 | 2247篇 |
2015年 | 2751篇 |
2014年 | 4059篇 |
2013年 | 6143篇 |
2012年 | 8959篇 |
2011年 | 9531篇 |
2010年 | 5304篇 |
2009年 | 4845篇 |
2008年 | 8459篇 |
2007年 | 9074篇 |
2006年 | 8651篇 |
2005年 | 8801篇 |
2004年 | 8442篇 |
2003年 | 7947篇 |
2002年 | 7759篇 |
2001年 | 1388篇 |
2000年 | 1143篇 |
1999年 | 1475篇 |
1998年 | 1654篇 |
1997年 | 1316篇 |
1996年 | 1274篇 |
1995年 | 1233篇 |
1994年 | 1050篇 |
1993年 | 1019篇 |
1992年 | 877篇 |
1991年 | 913篇 |
1990年 | 786篇 |
1989年 | 783篇 |
1988年 | 795篇 |
1987年 | 777篇 |
1986年 | 815篇 |
1985年 | 880篇 |
1984年 | 935篇 |
1983年 | 902篇 |
1982年 | 1151篇 |
1981年 | 1170篇 |
1980年 | 979篇 |
1979年 | 658篇 |
1978年 | 699篇 |
1977年 | 617篇 |
1976年 | 542篇 |
1975年 | 497篇 |
1974年 | 517篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
71.
Dr. Thomas C. Hardin Pharm.D. FCCP Dr. Steven C. Butler M.D. Dr. Sabine Ross M.D. Dr. John H. Wakeford Pharm.D. Dr. James H. Jorgensen Ph.D. 《Pharmacotherapy》1994,14(2):147-152
Study Objectives . To evaluate the pharmacodynamic antibacterial activity of ticarcillin-clavulanic acid (T-C) and ampicillin-sulbactam (A-S) combinations against reference bacterial strains in patients with end-stage renal disease maintained on long-term hemodialysis. Design . Randomized, crossover, controlled study. Setting . National Institutes of Health-funded general clinical research unit in a Veterans Administration Medical Center. Patients . Nine adult men with end-stage renal disease maintained on long-term hemodialysis. Two subjects did not complete the study due to problems of vascular access, and another withdrew for personal reasons. Interventions . On a nondialysis day, each subject was randomly administered either T-C 3.1 g or A-S 3 g as a slow intravenous infusion over 30 minutes. Serial blood samples were collected for measurement of antibiotic serum concentrations and determination of serum bactericidal titers. Following a washout period, the study was repeated with the alternative antibiotic combination. Measurements and Main Results . The mean observed apparent β-half-life of clavulanic acid was substantially shorter than that for the other three drugs. The bactericidal activity of both A-S and T-C against non-β-lactamase-producing (Nβ-LP) strains of S. aureus and E. coli was consistently high, as indicated by geometric mean SBTs of at least 1:5 at 24 hours. Against β-lactamase-producing (β-LP) S. aureus, the geometric mean SBTs for A-S were at least 1:25 throughout the study period, while the geometric mean SBTs for T-C decreased over 24 hours from 1:29 to 1:6. Against β-LP E. coli, the bactericidal activities for both A-S and T-C were poor, with geometric mean peak SBTs of only 1:6 and 1:3, respectively. The geometric mean SBT for T-C against this E. coli strain had declined to 1:1 at 6 hrs. Conclusion . Increasing the dosing interval for T-C in patients with end-stage renal disease may lead to periods of insufficient clavulanic acid to protect ticarcillin from β-lactamase degradation. 相似文献
72.
Dr. James C. Garrelts Pharm.D. W. Dale Horst Ph.D. Beryl Silkey Sc.M. Dr. Suzanne Gagnon M.D. 《Pharmacotherapy》1994,14(4):438-445
Study Objectives . To characterize patient sociodemographics and health, describe vancomycin treatment parameters and clinician-rated outcomes, and determine costs associated with treatment including preparation and administration, adverse events, and toxicity. Design . A prospective study to develop a model for costs associated with antibiotic treatment (vancomycin). Setting . A community hospital. Patients . One hundred adults with active infections. Interventions . Mean duration of therapy was 10 days, and most patients received 2000 mg/day. Serum concentrations were monitored in two of three patients. Detailed cost analyses were completed on a subset of 26 patients selected at random from the overall sample. Measurements and Main Results . Sepsis and skin and skin structure infections were the most common indications for vancomycin therapy. Treatment was effective in 81 patients, failed in 9, and was not evaluable in 10. Thirty-eight percent of patients experienced adverse events attributable to the drug. Phlebitis was common, and red man syndrome, nephrotoxicity, and ototoxicity were infrequent. Conclusions . Total cost of vancomycin treatment for 100 patients was $30,251: $23,855 for preparation and administration, $1710 for monitoring serum concentrations, and $4686 for treating adverse reactions. Drug costs accounted for only 55% of the total cost. Vancomycin is safe and effective, but phlebitis is underreported and significantly affects cost. 相似文献
73.
Dr. James Hui Ph.D. Dr. Yow-Ming C. Wang Ph.D. Dr. Appavu Chandrasekaran Ph.D. Dr. Douglas R. Geraets Pharm.D. Dr. James H. Caldwell M.D. Dr. Larry W. Robertson Ph.D. Dr. Richard H. Reuning Ph.D. 《Pharmacotherapy》1994,14(5):607-612
Study Objective . To compare digoxin tablets and liquid-filled capsules with respect to excretion of the drug and its metabolites in urine and feces at steady state. Design . A randomized, crossover trial, each period lasting 3 weeks, with no washout period. Setting . A university hospital. Patients . Six patients, five of whom were elderly, with histories of gastrointestinal disorders, such as hypochlorhydria, intestinal bacterial overgrowth, and inflammatory bowel disease. Interventions . The patients received digoxin once/day in either tablet or capsule form for 3 weeks, and then were switched to the other formulation. Total urinary and fecal excretion from the last 3 days of each regimen were analyzed for the drug and metabolites. Measurements and Main Results . No statistically significant differences were found between tablets and capsules in recovery of digoxin or its metabolites in urine or feces (p=0.05). One subject had a 4-fold increase in urinary drug excretion and 50% decrease in fecal excretion after taking the capsules compared with tablets. Intersubject variability in extent and type of metabolite excretion was greater than intrasubject variability. Conclusions . Fecal analyses may be an accurate way to classify patients as formers of digoxin reduction products. 相似文献
74.
Haiyung Cheng Jules I. Schwartz Charles Lin Raju D. Amin James R. Seibold Kenneth C. Lasseter David L. Ebel Dominick J. Tocco J. Douglas Rogers 《Biopharmaceutics & drug disposition》1994,15(5):409-418
MK-679 (R(?)-3-((3-(2-(7-chloro-2-quinolinyl)ethenyl)phenyl)(3-(dimethylamino)-3-oxopropyl)thio)methyl)thio(propanoic acid) is a potent and specific LTD4-receptor antagonist. The disposition of MK-679 was investigated in a three-way crossover study in 12 healthy males receiving single intravenous doses of 75, 250, and 500 mg of MK-679. A greater than proportional increase in the area under the plasma concentration—time curve of MK-679 was observed with increase in dose. The plasma concentration data for each subject fitted well to the differential equations for a two-compartment model with linear tissue distribution and Michaelis-Menten elimination from the central compartment, indicating that the elimination of MK-679 in humans is saturable. In a previous study, the disposition of MK-679 in humans was also dose-dependent when given together with its S(+)-isomer, L-668,018. Thus, the disposition of MK-679 in humans is dose-dependent regardless of the presence of its stereoisomer. Also, the bioavailability of MK-679 was determined in six healthy males receiving simultaneously an oral dose of 250 mg of MK-679 and intravenous infusion of 1 mg 14C-MK-679. Results of this study indicate that the oral bioavailability of MK-679 is nearly quantitative. 相似文献
75.
76.
77.
78.
79.
80.
ANAPHYLAXIS IS A SEVERE SYSTEMIC ALLERGIC reaction that is potentially fatal. It requires prompt recognition and immediate management. Anaphylaxis has a rapid onset with multiple organ–system involvement and is mostly caused by specific antigens in sensitized individuals. Reactions typically follow a uniphasic course, however, 20% will be biphasic in nature. The second phase usually occurs after an asymptomatic period of 1–8 hours, but there may be a 24-hour delay. Protracted anaphylaxis may persist beyond 24 hours. Concurrent β-blocker therapy may adversely affect the response to management. Epinephrine is the treatment of choice and should be administered immediately. Secondary measures include circulatory support, H1 and H2 antagonists, corticosteroids and, occasionally, bronchodilators. Post-treatment observation of these patients is necessary, and they should remain within ready access of emergency care for the following 48 hours. 相似文献